Shots:

• GSK will invest $163M (€150m) in CureVac for a 10% stake to collaborate for the research- development- manufacturing- and commercialization of up to five mRNA-based vaccines and mAbs targeting infectious disease pathogens excluding CureVac’s existing COVID-19 mRNA and rabies vaccines research programs
• CureVac to receive $137M (€120m) as upfront- $34.3 (€30m) as one-time reimbursable payment and is eligible to receive up to $366M (€320m) as development and regulatory milestones- $435M (€380m) as commercial milestones along with royalties on product sales
• CureVac will lead pre/clinical-development till P-I trial after which GSK will develop & commercialize the therapies. Moreover- CureVAc will receive R&D funding from GSK and will be responsible for the GMP manufacturing of the candidates as well as retain the commercialization rights for all products in selected countries

  Ref: GSK | Image: GSK